Ep. 255, Chapter 2: Hard Questions Investors Ask with Yaniv Sneor

13:02 -- 24:41

Sneor details Mid Atlantic Bio Angels’ considerations when deliberating whether to invest in a biotech startup. The group prioritizes understanding how each biotech plans to monetize its opportunity and achieve a successful exit within five to seven years — looking for a clear path, potential acquirers, and comparable deals — so commercial mindset is as important as scientific prowess. MAB Angels prefers to participate in smaller, syndicated investment rounds of $0.25-$1 million, which allow companies to maintain control and provide consistent progress for investors. Sneor notes that the inherent maturity of biotech companies driven by rigorous data generation and regulatory requirements translates to higher quality investment opportunities.